

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Veli-Matti LEHTOLA, et al.
Appln. No.: 10/783,024
Filed: February 23, 2004
For: SOLID FORMULATIONS OF
OSPEMIFENE
Attorney Docket No: 13601-016

Examiner: Hasan Syed Ahmed
Art Unit: 1615
Confirmation No.: 3763

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

In accordance with the duty of disclosure under 37 CFR §1.56 and §§1.97-1.98, and more particularly in accordance with 37 CFR §1.97(b), Applicant hereby cites the following reference(s):

OTHER ART – NON PATENT LITERATURE DOCUMENTS	
Chueschov, "Industrial technology of drugs", 353-355 (1999).	
BI Dianzhou, Chinese Textbook cited by the examiner, Pharmaceuticals, Fourth Edition (2003), People's Medical Publishing House	

Applicant is enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 CFR §1.98(a)(2). Pursuant to the undersigned attorney's obligation and duties under 37 CFR §§ 1.56 and 1.98(a)(3) and (c), either English language abstracts, partial translations, or full translations are included for patent documents which are not in English for the express purpose of providing a concise explanation of the references to the Patent and Trademark Office with the opportunity to evaluate the same. Applicant respectfully requests the Examiner's consideration of the above reference(s) and entry thereof into the record of this application.

By submitting this Statement, Applicant is attempting to fully comply with the duty of candor and good faith mandated by 37 CFR §1.56. As such, this Statement is not

intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 CFR §1.56(a).

The Applicant or Applicants have calculated no fee to be due in connection with the filing of this Information Disclosure Statement. However, the Director is authorized to charge any fee deficiency associated with the filing of this Information Disclosure Statement to a deposit account, as authorized in the Transmittal accompanying this Information Disclosure Statement.

Respectfully submitted,

July 30, 2010

Date

/Bonnie R. Shaw/

Bonnie R. Shaw, Reg. No. 60,493

Attorney for Applicants